Nurix Therapeutics
NRIX----
Q2 FY2026 EarningsQ2 FY26 revenue was $9.0M, down 79.5% YoY, primarily due to high license revenue bases in the prior year. Net loss expanded to $89.5M, with diluted EPS at ($0.81). A landmark $2.3B global collaboration with Roche for bexobrutideg was announced, including a $700M upfront payment, set to boost pro-forma cash to $1.14B and fund expansion into MS and CSU.
Financial report interval: 2026.03.03 - 2026.05.31
Preview: Nurix Therapeutics(NRIX) predict that the Revenue is 9.043 M (-79.47%), Miss estimate;the EBIT is -94.2 M (-94.95%), Miss estimate;the EPS is -0.81 (-55.77%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.01B79.47%
0.01B69.56%
-0.00B9.91%
EBITMiss expectations
-0.09B94.95%
-0.09B76.14%
-0.01B18.81%
EPSMiss expectations
-0.8155.77%
-0.724839.38%
-0.085216.39%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf